Last reviewed · How we verify
Gefitinib, Cisplatin and Radiotherapy
Gefitinib, Cisplatin and Radiotherapy is a EGFR tyrosine kinase inhibitor Small molecule drug developed by AstraZeneca. It is currently in Phase 2 development for Non-small cell lung cancer.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Used for Non-small cell lung cancer.
At a glance
| Generic name | Gefitinib, Cisplatin and Radiotherapy |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gefitinib is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the signaling pathway that promotes the growth and survival of cancer cells.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Fatigue
Key clinical trials
- Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma (NA)
- Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery (PHASE2)
- Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer (PHASE2)
- Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery (PHASE1)
- Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery (PHASE3)
- Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer (PHASE1)
- Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gefitinib, Cisplatin and Radiotherapy CI brief — competitive landscape report
- Gefitinib, Cisplatin and Radiotherapy updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Gefitinib, Cisplatin and Radiotherapy
What is Gefitinib, Cisplatin and Radiotherapy?
How does Gefitinib, Cisplatin and Radiotherapy work?
What is Gefitinib, Cisplatin and Radiotherapy used for?
Who makes Gefitinib, Cisplatin and Radiotherapy?
What drug class is Gefitinib, Cisplatin and Radiotherapy in?
What development phase is Gefitinib, Cisplatin and Radiotherapy in?
What are the side effects of Gefitinib, Cisplatin and Radiotherapy?
What does Gefitinib, Cisplatin and Radiotherapy target?
Related
- Drug class: All EGFR tyrosine kinase inhibitor drugs
- Target: All drugs targeting EGFR
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Compare: Gefitinib, Cisplatin and Radiotherapy vs similar drugs
- Pricing: Gefitinib, Cisplatin and Radiotherapy cost, discount & access